Previous Close | 18.71 |
1-Year Change | -34.05% |
6-Months Change | -25.58% |
3-Months Change | -23.23% |
Moving Avg (50d) | 19.955 |
Moving Avg (200d) | 24.704 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.0B |
Beta (3-Years) | 1.61 |
Revenue Growth (ttm) | 2.51% |
Net Profit Margin (ttm) | -70.69% |
Return On Assets (ttm) | -22.76% |
EPS (ttm) | -1.71 |
PE Ratio (ttm) | -10.94 |
Dividend Yield | % |
Asset Description: | Arrowhead Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-14 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
19.084 | 19.645 | 20.02 | 20.581 | 21.516 | 22.452 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of... Wikipedia